SM
AUPH icon

SG3 Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

SG3 Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$686K – 956
2021
Q4 		$686K Sell
30,000
-30,600
-50% -$725K 0.01% 561
2021
Q3 		$1.34M Hold
60,600
– – 0.04% 388
2021
Q2 		$785K Sell
60,600
-139,400
-70% -$1.78M 0.03% 538
2021
Q1 		$2.6M Sell
200,000
-150,000
-43% -$2.18M 0.06% 335
2020
Q4 		$4.84M Buy
350,000
+200,000
+133% +$2.91M 0.09% 204
2020
Q3 		$2.21M Buy
150,000
+90,000
+150% +$1.3M 0.08% 255
2020
Q2 		$975K Buy
+60,000
New +$961K 0.07% 291

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SG3 Management's AUPH Position: Q1 2022 in Review

SG3 Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 42,500 shares — an estimated $657K sold.

SG3 Management first reported a position in AUPH in Q2 2020 and held it in 6 quarters. The position peaked at $1.5M in Q3 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

  • SG3 Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 42,500 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $657K.
  • SG3 Management first reported a position in Aurinia Pharmaceuticals in Q2 2020 and held it in 6 quarters.
  • SG3 Management's Aurinia Pharmaceuticals position peaked at $1.5M in Q3 2021.
  • 184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.